Loading...
•
Dec 31, 2019
Elanco Q4 2019 Earnings Report
Elanco reported a decrease in revenue and a net loss for Q4 2019, but highlighted progress in its core business and the Bayer Animal Health acquisition.
Key Takeaways
Elanco Animal Health reported Q4 2019 financial results, with total revenue decreasing by 2% to $787 million. The company experienced a net loss of $9.5 million, or $0.03 per diluted share. However, core revenue, excluding strategic exits, increased by 1% at constant currency, and the company made progress with the Bayer Animal Health acquisition.
Total revenue decreased by 2% to $787 million, but core revenue (excluding strategic exits) increased by 1% at constant currency.
Net loss for the quarter was $9.5 million, or $0.03 per diluted share.
Companion Animal Therapeutics revenue increased 33%, driven by increased volume and price.
The company is making significant progress with the Bayer Animal Health acquisition, expecting a mid-2020 close.
Forward Guidance
Elanco confirmed the full year 2020 guidance provided in January, representing standalone Elanco only and including contribution from products Elanco has announced they will divest. The guidance does not consider any financing elements but includes costs associated with the stand up of Elanco and integration planning for the Bayer AG animal health acquisition.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...